Connect
MJA
MJA

Supraventricular tachycardia

Caroline Medi, Jonathan M Kalman and Saul B Freedman
Med J Aust 2009; 190 (5): 255-260.
  • Caroline Medi1,2
  • Jonathan M Kalman1,2
  • Saul B Freedman3,4

  • 1 Department of Cardiology, Royal Melbourne Hospital, Melbourne, VIC.
  • 2 Department of Medicine, University of Melbourne, Melbourne, VIC.
  • 3 Department of Cardiology, Concord Clinical School, Concord Hospital, Sydney, NSW.
  • 4 Vascular Biology Laboratory, ANZAC Research Institute, University of Sydney, Sydney, NSW.

Correspondence: jon.kalman@mh.org.au

Competing interests:

None identified.

  • 1. Medi C, Hankey GJ, Freedman SB. Atrial fibrillation. Med J Aust 2007; 186: 197-202. <MJA full text>
  • 2. Orejarena LA, Vidaillet H, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol 1998; 31: 150-157.
  • 3. Rodriguez LM, De Chillou C, Schlapfer J, et al. Age at onset and gender of patients with different types of supraventricular tachycardias. Am J Cardiol 1992; 70: 1213-1215.
  • 4. Goyal R, Zivin A, Souza J, et al. Comparison of the ages of tachycardia onset in patients with atrioventricular nodal reentrant tachycardia and accessory pathway-mediated tachycardia. Am Heart J 1996; 132: 765-767.
  • 5. Rosano G, Leonardo F, Sarrel PM, et al. Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet 1996; 347: 786-788.
  • 6. Tada H, Oral H, Greenstein R, et al. Analysis of age of onset of accessory pathway-mediated tachycardia in men and women. Am J Cardiol 2002; 89: 470-471.
  • 7. Porter MJ, Morton JB, Denman R, et al. Influence of age and gender on the mechanism of supraventricular tachycardia. Heart Rhythm 2004; 1: 393-396.
  • 8. Lessmeier TJ, Gamperling D, Johnson-Liddon V, et al. Unrecognized paroxysmal supraventricular tachycardia. Potential for misdiagnosis as panic disorder. Arch Intern Med 1997; 157: 537-543.
  • 9. Fenelon G, Wijns W, Andries E, et al. Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol 1996; 19: 95-106.
  • 10. Chen SA, Yang CJ, Chiang CE, et al. Reversibility of left ventricular dysfunction after successful catheter ablation of supraventricular reentrant tachycardia. Am Heart J 1992; 124: 1512-1516.
  • 11. Kistler PM, Sanders P, Fynn SP, et al. Electrophysiological and electrocardiographic characteristics of focal atrial tachycardia originating from the pulmonary veins: acute and long-term outcomes of radiofrequency ablation. Circulation 2003; 108: 1968-1975.
  • 12. Atie J, Brugada P, Brugada J, et al. Clinical and electrophysiologic characteristics of patients with antidromic circus movement tachycardia in the Wolff–Parkinson–White syndrome. Am J Cardiol 1990; 66: 1082-1091.
  • 13. Akhtar M, Jazayeri MR, Sra J, et al. Atrioventricular nodal reentry. Clinical, electrophysiological, and therapeutic considerations. Circulation 1993; 88: 282-295.
  • 14. Wang YS, Scheinman MM, Chien WW, et al. Patients with supraventricular tachycardia presenting with aborted sudden death: incidence, mechanism and long-term follow-up. J Am Coll Cardiol 1991; 18: 1711-1719.
  • 15. Roberts-Thomson KC, Kistler PM, Kalman JM. Focal atrial tachycardia I: clinical features, diagnosis, mechanisms, and anatomic location. Pacing Clin Electrophysiol 2006; 29: 643-652.
  • 16. Roberts-Thomson KC, Kistler PM, Kalman JM. Focal atrial tachycardia II: management. Pacing Clin Electrophysiol 2006; 29: 769-778.
  • 17. Saoudi N, Cosio F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a Statement from a Joint Expert Group from the Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 22: 1162-1182.
  • 18. Kistler PM, Roberts-Thomson KC, Haqqani H, et al. P-wave morphology in focal atrial tachycardia: development of an algorithm to predict anatomic site of origin. J Am Coll Cardiol 2006; 48: 1010-1017.
  • 19. Kastor JA. Multifocal atrial tachycardia. N Engl J Med 1990; 322: 1713-1717.
  • 20. Morillo CA, Klein GJ, Thakur RA, et al. Mechanism of “inappropriate” sinus tachycardia. Role of sympathovagal balance. Circulation 1994; 90: 873-877.
  • 21. Krahn AD, Yee R, Klein GJ, et al. Inappropriate sinus tachycardia: evaluation and therapy. J Cardiovasc Electrophysiol 1995; 6: 1124-1128.
  • 22. Yusuf S, Camm JA. Deciphering the sinus tachycardias. Clin Cardiol 2005; 28: 267-276.
  • 23. Low PA, Opfer-Gehrking TL, Textor SC. Postural tachycardia syndrome (POTS). Neurology 1995; 45: S19-S25.
  • 24. Grubb BP, Kanjwal MY, Kosinski DJ. Review: The postural orthostatic tachycardia syndrome: current concepts in pathophysiology diagnosis and management. J Interv Card Electrophysiol 2001; 5: 9-16.
  • 25. Di Marco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med 1990; 113: 104-110.
  • 26. Di Marco JP, Sellers TD, Berne RM, et al. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 1983; 68: 1254-1263.
  • 27. Dougherty AH, Jackman WM, Naccarelli GV, et al. Acute conversion of paroxysmal supraventricular tachycardia with intravenous diltiazem. IV Diltiazem Study Group. Am J Cardiol 1992; 70: 587-592.
  • 28. Sung RJ, Elser B, McAllister RG Jr. Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Ann Intern Med 1980; 93: 682-689.
  • 29. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias — executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias). J Am Coll Cardiol 2003; 42: 1493-1531.
  • 30. Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol 2000; 23: 1020-1028.
  • 31. Winniford MD, Fulton, KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol 1984; 54: 1138-1139.
  • 32. Klein GJ, Bashore TM, Sellers TD, et al. Ventricular fibrillation in the Wolff–Parkinson–White syndrome. N Engl J Med 1979; 301: 1080-1085.
  • 33. Yee R, Gulamhusein S, Klein GJ. Combining verapamil and propranolol for supraventricular tachycardia. Am J Cardiol 1984; 53: 757-763.
  • 34. Henthorn RW, Waldo AL, Anderson JL, et al. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. Circulation 1991; 83: 119-125.
  • 35. Kunze KP, Schlutter M, Kuck KH. Sotalol in patients with Wolff–Parkinson–White syndrome. Circulation 1987; 75: 1050-1057.
  • 36. Lee KL, Tai YT. Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: efficacy and safety. Clin Cardiol 1997; 20: 372-377.
  • 37. Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial node If channels by ivabradine. J Gen Physiol 2002; 120: 1-13.
  • 38. van Lieshout JJ, ten Harkel AD, Wieling W. Physical manoeuvres for combating orthostatic dizzyness in autonomic failure. Lancet 1992; 339: 897-898.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.